Extended Data Fig. 2: Tumour mutational features in STSs and LTSs of PDAC .
From: Neoantigen quality predicts immunoediting in survivors of pancreatic cancer
(a) Whole-exome sequencing depth and (b) number of synonymous mutations in primary and recurrent PDACs from STSs and LTSs. (c) Oncoprints of driver mutation frequencies in primary and recurrent PDACs. Frequencies = percentage of patients in each cohort that harbor corresponding driver gene mutations. (d) Frequency of primary (left) and recurrent (right) PDACs with mutations in â„ 3 oncogenes. (e) Number of nonsynonymous mutations (TMB) versus number of mutations in oncogenes in primary and recurrent PDACs. n = individual tumours. Horizontal bars = median. P value by two-tailed Mann-Whitney U-test.
